Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Predominantly, magnetic resonance imaging (MRI) studies in animal models of Parkinson's disease (PD) have focused on alterations in T 2 water 1 H relaxation or 1 H MR spectroscopy (MRS), whilst potential morphological changes and their relationship to histological or behavioural outcomes have not been appropriately addressed. Therefore, in this study we have utilised MRI to scan in vivo brains from rodents bearing a nigrostriatal lesion induced by intranigral injection of the proteasome inhibitor lactacystin. Results: Lactacystin induced parkinsonian-like behaviour, characterised by impaired contralateral forelimb grip strength and increased contralateral circling in response to apomorphine. T 2-weighted MRI, 3-weeks post-lesion, revealed significant morphological changes in PD-relevant brain areas, including the striatum and ventral midbrain in addition to a decrease in T 2 water 1 H relaxation in the substantia nigra (SN), but not the striatum. Post-mortem histological analyses revealed extensive dopaminergic neuronal degeneration and α-synuclein aggregation in the SN. However, extensive neuronal loss could also be observed in extra-nigral areas, suggesting non-specific toxicity of lactacystin. Iron accumulation could also be observed throughout the midbrain reflecting changes in T 2. Importantly, morphological, but not T 2 relaxivity changes, were significantly associated with both behavioural and histological outcomes in this model. Conclusions: A pattern of morphological changes in lactacystin-lesioned animals has been identified, as well as alterations in nigral T 2 relaxivity. The significant relationship of morphological changes with behavioural and histological outcomes in this model raises the possibility that these may be useful non-invasive surrogate markers of nigrostriatal degeneration in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
Dexter, D. T., Wells, F. R., Lee, A. J., Agid, F., Agid, Y., Jenner, P., & Marsden, C. D. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07264.x · Cited by 1,149 · cited 2×
“Overall, these data are also consistent with MRI findings in PD patients reporting decreased T2 relaxation time in the SN [15-18] and biochemical measurements reporting increased iron accumulation in the SN of PD patients [48,49].”
ResultDay, M., Wang, Z., Ding, J., An, X., Ingham, C. A., Shering, A. F., Wokosin, D., Ilijic, E., Sun, Z., Sampson, A. R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1632 · Cited by 745
Iron in the basal ganglia in Parkinson's disease
Griffiths, P. D., Dobson, B. R., Jones, G. R., & Clarke, D. T. (1999) · Brain · doi:10.1093/brain/122.4.667 · Cited by 229
Voxel‐based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy
Brenneis, C., Seppi, K., Schocke, M. F., Müller, J., Luginger, E., Bösch, S., Löscher, W. N., Büchel, C., Poewe, W., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10502 · Cited by 167 · cited 1×
“In early-stage iPD, both normal [6,7] and partial reductions [8-10] in grey matter volume (GMV) of the BG have been reported [4].”
BackgroundNeuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration
Zhang, X., Xie, W., Qu, S., Pan, T., Wang, X., & Le, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.150 · Cited by 87 · cited 3×
“This relatively recently developed model has been suggested to be a novel, pathologically relevant model of PD [34-36], which has already been used with some success in neuroprotection studies [35-38].”
BackgroundResult
Cited by
Antal, A., Alekseichuk, I., Bikson, M., Brockmöller, J., Brunoni, A. R., Chen, R., Cohen, L. G., Dowthwaite, G., Ellrich, J., Flöel, A., et al. (2017) · Clinical Neurophysiology · doi:10.1016/j.clinph.2017.06.001 · Cited by 1,301
Alpha-synuclein oligomers: a new hope
Bengoa-Vergniory, N., Roberts, R. F., Wade-Martins, R., & Alegre-Abarrategui, J. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1755-1 · Cited by 338
Protein degradation pathways in Parkinson’s disease: curse or blessing
Ebrahimi-Fakhari, D., Wahlster, L., & McLean, P. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1004-6 · Cited by 253
Vernon, A. C., Natesan, S., Modo, M., & Kapur, S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.11.010 · Cited by 173
Self-citationNeuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease
Broom, L., Marinova-Mutafchieva, L., Sadeghian, M., Davis, J. B., Medhurst, A. D., & Dexter, D. T. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.12.026 · Cited by 96
Metadata
- Authors
- Vernon, A. C., Johansson, S. M., & Modo, M. M.
- Venue
- BMC Neuroscience
- Published
- 2010-01-05
- Volume
- 11
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1471-2202 (ISSN-L)
- OpenAlex
- W2037671369
- Cited by
- 146
- References
- 7
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease. https://app.cochat.ai/papers/10.1186/1471-2202-11-1
- The paper
- Vernon, A. C., Johansson, S. M., & Modo, M. M. (2010). Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease. BMC Neuroscience. https://doi.org/10.1186/1471-2202-11-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.